Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
NCI study estimates more than 2 million women could benefit from tamoxifen
April 22nd, 2003
More than 10 million women in the United States have a high enough risk of developing breast cancer that they could consider taking the breast cancer chemoprevention drug tamoxifen, according to Andrew N. Freedman, PhD, and his colleagues at the National Cancer Institute (NCI). When the scientists examined this group of women using a risk-benefit analysis of the drug, they found that more than 2 million women would be likely to derive overall benefit from the drug without undue risks. The results were reported in the April 2, 2003, issue of the Journal of the National Cancer Institute. Tamoxifen was approved 5 years ago as the first drug to...
Source: Cancer Weekly (2003-04-22)
|
